Enzymatica AB (publ) ENZY

Updated: 9 Aug 2026

NASDAQ | Biotech | Medical Technology / Healthcare

No signal published yet

We already track Enzymatica and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.

Follow Enzymatica free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Free
No email, no account, no signup.
Exchange
NASDAQ
Type
Biotech
Sector
Medical Technology / Healthcare
We're already tracking Enzymatica AB (publ) — here are the latest events we've registered

Recent News

  • On July 16, 2026, Enzymatica published its interim report for the second quarter of 2026, reporting net sales of SEK 7.1 million and an operating result of SEK -12.6 million. During the period, the company appointed a new Nordic Marketing and Sales Director and partnered with the women's cycling team Unibet Rose Rockets to increase ColdZyme brand visibility.

What Firelda Watch includes for Enzymatica AB (publ)

Add the company to your watchlist and get all of this automatically.

  • Free: 3 companies on your watchlist
  • Change history and monitoring for every company you follow
  • Sunday weekly brief — a short weekly roundup
  • Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Enzymatica AB (publ) will be delivered in the same format.

Want to follow Enzymatica AB (publ)? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.

Follow Enzymatica free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Enzymatica AB (publ) ENZY
Enzymatica — follow and we'll monitor it
Follow Enzymatica free Follow free
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.